<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02707523</url>
  </required_header>
  <id_info>
    <org_study_id>FWA00005960</org_study_id>
    <nct_id>NCT02707523</nct_id>
  </id_info>
  <brief_title>Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children</brief_title>
  <official_title>Prospective Pilot Clinical Trial of Azithromycin Treatment In RSV-induced Respiratory Failure In Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo-controlled phase 2 trial will be conducted at a single
      tertiary pediatric intensive care unit (PICU). The study will include children with RSV
      infection who were admitted to the pediatric intensive care unit and require respiratory
      support via positive pressure ventilation (invasive and noninvasive).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible participants include all children admitted to the PICU at Children's of Alabama with
      a diagnosis of RSV infection and requiring positive pressure ventilation, invasive or
      noninvasive, including bilevel positive airway pressure (BiPAP) or high flow nasal cannula
      (HFNC) oxygen (ie, &gt;1 L/kg/min of flow, with 5 L/min flow for children weighing &lt;5 kg).
      During hospitalization, all patients will be treated according to the American Academy of
      Pediatrics guidelines for the management of bronchiolitis, primarily supportive care.
      Participants will then be randomized according to a permuted-block design to receive either
      placebo (saline) or AZM (Fresenius Kabi) at 10mg/kg/d (ie, standard dose) or 20mg/kg/d (ie,
      high dose) intravenously every 24 hours for 3 days. All biologic samples collected will be
      analyzed in the PI's lab at the University of Alabama at Birmingham. Drug pharmacokinetics
      will be performed at the Pharmaceutical Sciences Research Institute of Samford University,
      Birmingham, AL.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">June 20, 2020</completion_date>
  <primary_completion_date type="Actual">February 6, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participant, clinical providers and study staff are masked to the intervention. The random assignment of treatment was determined by random permutation. A statistician generated the randomization schedule and provided the randomization schedule (with randomization IDs) in an excel file to the study pharmacist in charge of dispensing the appropriate treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0</measure>
    <time_frame>Baseline through Day 3</time_frame>
    <description>To determine the safety profile of AZM at 10 mg/kg and 20 mg/kg IV X 3 days in children with RSV-induced respiratory failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nasal Total Matrix Metalloproteinase (MMP)-9 Level</measure>
    <time_frame>Day 3</time_frame>
    <description>To determine the concentration of total MMP-9 levels in the nasal compartment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic-Plasma Half Life of AZM</measure>
    <time_frame>From baseline to 72 hours post treatment</time_frame>
    <description>Measurement of AZM half life in the plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic-Lung Half Life of AZM</measure>
    <time_frame>From baseline to 72 hours post treatment</time_frame>
    <description>Measurement of AZM half life in the lung</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Mechanical Ventilation in Days</measure>
    <time_frame>Pre-treatment through 2 weeks</time_frame>
    <description>Duration of mechanical ventilation in days for enrolled subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of BiPAP in Days</measure>
    <time_frame>Pre-treatment through 2 weeks</time_frame>
    <description>Duration of BiPAP in days for enrolled subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of High Flow Nasal Cannula in Days</measure>
    <time_frame>Pre-treatment through 2 weeks</time_frame>
    <description>Duration of High Flow Nasal Cannula in days for enrolled subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Oxygenation in Days</measure>
    <time_frame>Pre-treatment through 2 weeks</time_frame>
    <description>Duration of oxygenation in days for enrolled subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization in Days</measure>
    <time_frame>Pre-treatment through 2 weeks</time_frame>
    <description>Duration of hospitalization in days for enrolled subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of PICU Stay in Days</measure>
    <time_frame>Pre-treatment through 2 weeks</time_frame>
    <description>Duration of PICU stay in days for enrolled subjects</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lung Matrix Metalloproteinase (MMP) Level</measure>
    <time_frame>Day 3</time_frame>
    <description>To determine the concentration of MMP-9 levels in the lung compartment</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Respiratory Syncytial Virus</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo controlled (normal saline) daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin (10 mg/kg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg/kg IV Azithromycin daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin (20 mg/kg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg/kg IV Azithromycin daily for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin 10 mg</intervention_name>
    <arm_group_label>Azithromycin (10 mg/kg)</arm_group_label>
    <other_name>Zithromax</other_name>
    <other_name>Z-Pak</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin 20mg</intervention_name>
    <arm_group_label>Azithromycin (20 mg/kg)</arm_group_label>
    <other_name>Zithromax</other_name>
    <other_name>Z-Pak</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admission to the PICU with RSV infection

          -  Need for positive pressure ventilation (invasive and non-invasive)

          -  Randomization and drug/placebo initiation within 48 hours of admission to Pediatric
             Intensive Care Unit

        Exclusion Criteria:

          -  Azithromycin use within 7 days of PICU admission

          -  Contraindication to azithromycin use including:

               -  Patients with electrocardiogram QT interval corrected for heart rate (Qtc) â‰¥ 450
                  ms

               -  Patients with significant hepatic impairment (direct bilirubin &gt;1.5 mg/dL)

               -  Known hypersensitivity to azithromycin, erythromycin, any macrolide, or ketolide
                  drug

               -  Cardiac arrhythmia

          -  History of pyloric stenosis

          -  Immunocompromised children (any cause)

          -  Current use of any medication known to cause QT prolongation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Kong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 20, 2016</study_first_submitted>
  <study_first_submitted_qc>March 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2016</study_first_posted>
  <results_first_submitted>May 8, 2020</results_first_submitted>
  <results_first_submitted_qc>May 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 27, 2020</results_first_posted>
  <disposition_first_submitted>April 23, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>April 23, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 28, 2020</disposition_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Michele Kong</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>RSV</keyword>
  <keyword>respiratory support</keyword>
  <keyword>ICU</keyword>
  <keyword>Azithromycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT02707523/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Placebo controlled (normal saline) daily for 3 days</description>
        </group>
        <group group_id="P2">
          <title>Azithromycin (10 mg/kg)</title>
          <description>10 mg/kg IV Azithromycin daily for 3 days</description>
        </group>
        <group group_id="P3">
          <title>Azithromycin (20 mg/kg)</title>
          <description>20 mg/kg IV Azithromycin daily for 3 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Placebo controlled (normal saline) daily for 3 days</description>
        </group>
        <group group_id="B2">
          <title>Azithromycin (10 mg/kg)</title>
          <description>10 mg/kg IV Azithromycin daily for 3 days</description>
        </group>
        <group group_id="B3">
          <title>Azithromycin (20 mg/kg)</title>
          <description>20 mg/kg IV Azithromycin daily for 3 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.8" spread="11"/>
                    <measurement group_id="B2" value="21.6" spread="29"/>
                    <measurement group_id="B3" value="20.2" spread="23"/>
                    <measurement group_id="B4" value="17.5" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0</title>
        <description>To determine the safety profile of AZM at 10 mg/kg and 20 mg/kg IV X 3 days in children with RSV-induced respiratory failure</description>
        <time_frame>Baseline through Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Placebo controlled (normal saline) daily for 3 days
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin (10 mg/kg)</title>
            <description>10 mg/kg IV Azithromycin daily for 3 days
Azithromycin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Azithromycin (20 mg/kg)</title>
            <description>20 mg/kg IV Azithromycin daily for 3 days
Azithromycin 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0</title>
          <description>To determine the safety profile of AZM at 10 mg/kg and 20 mg/kg IV X 3 days in children with RSV-induced respiratory failure</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Nasal Total Matrix Metalloproteinase (MMP)-9 Level</title>
        <description>To determine the concentration of total MMP-9 levels in the nasal compartment</description>
        <time_frame>Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Placebo controlled (normal saline) daily for 3 days
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin (10 mg/kg)</title>
            <description>10 mg/kg IV Azithromycin daily for 3 days
Azithromycin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Azithromycin (20 mg/kg)</title>
            <description>20 mg/kg IV Azithromycin daily for 3 days
Azithromycin 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Total Matrix Metalloproteinase (MMP)-9 Level</title>
          <description>To determine the concentration of total MMP-9 levels in the nasal compartment</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="545" spread="708"/>
                    <measurement group_id="O2" value="267" spread="301"/>
                    <measurement group_id="O3" value="413" spread="814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic-Plasma Half Life of AZM</title>
        <description>Measurement of AZM half life in the plasma</description>
        <time_frame>From baseline to 72 hours post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Placebo controlled (normal saline) daily for 3 days
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin (10 mg/kg)</title>
            <description>10 mg/kg IV Azithromycin daily for 3 days
Azithromycin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Azithromycin (20 mg/kg)</title>
            <description>20 mg/kg IV Azithromycin daily for 3 days
Azithromycin 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic-Plasma Half Life of AZM</title>
          <description>Measurement of AZM half life in the plasma</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="76" spread="17"/>
                    <measurement group_id="O3" value="102" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic-Lung Half Life of AZM</title>
        <description>Measurement of AZM half life in the lung</description>
        <time_frame>From baseline to 72 hours post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Placebo controlled (normal saline) daily for 3 days
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin (10 mg/kg)</title>
            <description>10 mg/kg IV Azithromycin daily for 3 days
Azithromycin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Azithromycin (20 mg/kg)</title>
            <description>20 mg/kg IV Azithromycin daily for 3 days
Azithromycin 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic-Lung Half Life of AZM</title>
          <description>Measurement of AZM half life in the lung</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="78" spread="31"/>
                    <measurement group_id="O3" value="385" spread="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Mechanical Ventilation in Days</title>
        <description>Duration of mechanical ventilation in days for enrolled subjects</description>
        <time_frame>Pre-treatment through 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Placebo controlled (normal saline) daily for 3 days
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin (10 mg/kg)</title>
            <description>10 mg/kg IV Azithromycin daily for 3 days
Azithromycin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Azithromycin (20 mg/kg)</title>
            <description>20 mg/kg IV Azithromycin daily for 3 days
Azithromycin 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Mechanical Ventilation in Days</title>
          <description>Duration of mechanical ventilation in days for enrolled subjects</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="3.4"/>
                    <measurement group_id="O2" value="5.6" spread="5.5"/>
                    <measurement group_id="O3" value="2.6" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of BiPAP in Days</title>
        <description>Duration of BiPAP in days for enrolled subjects</description>
        <time_frame>Pre-treatment through 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Placebo controlled (normal saline) daily for 3 days
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin (10 mg/kg)</title>
            <description>10 mg/kg IV Azithromycin daily for 3 days
Azithromycin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Azithromycin (20 mg/kg)</title>
            <description>20 mg/kg IV Azithromycin daily for 3 days
Azithromycin 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of BiPAP in Days</title>
          <description>Duration of BiPAP in days for enrolled subjects</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="13.2"/>
                    <measurement group_id="O2" value="0.4" spread="1.5"/>
                    <measurement group_id="O3" value="0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of High Flow Nasal Cannula in Days</title>
        <description>Duration of High Flow Nasal Cannula in days for enrolled subjects</description>
        <time_frame>Pre-treatment through 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Placebo controlled (normal saline) daily for 3 days
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin (10 mg/kg)</title>
            <description>10 mg/kg IV Azithromycin daily for 3 days
Azithromycin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Azithromycin (20 mg/kg)</title>
            <description>20 mg/kg IV Azithromycin daily for 3 days
Azithromycin 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of High Flow Nasal Cannula in Days</title>
          <description>Duration of High Flow Nasal Cannula in days for enrolled subjects</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="4.9"/>
                    <measurement group_id="O2" value="2.4" spread="2"/>
                    <measurement group_id="O3" value="2.3" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Oxygenation in Days</title>
        <description>Duration of oxygenation in days for enrolled subjects</description>
        <time_frame>Pre-treatment through 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Placebo controlled (normal saline) daily for 3 days
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin (10 mg/kg)</title>
            <description>10 mg/kg IV Azithromycin daily for 3 days
Azithromycin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Azithromycin (20 mg/kg)</title>
            <description>20 mg/kg IV Azithromycin daily for 3 days
Azithromycin 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Oxygenation in Days</title>
          <description>Duration of oxygenation in days for enrolled subjects</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="8.7"/>
                    <measurement group_id="O2" value="9.6" spread="5.8"/>
                    <measurement group_id="O3" value="6.6" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Hospitalization in Days</title>
        <description>Duration of hospitalization in days for enrolled subjects</description>
        <time_frame>Pre-treatment through 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Placebo controlled (normal saline) daily for 3 days
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin (10 mg/kg)</title>
            <description>10 mg/kg IV Azithromycin daily for 3 days
Azithromycin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Azithromycin (20 mg/kg)</title>
            <description>20 mg/kg IV Azithromycin daily for 3 days
Azithromycin 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Hospitalization in Days</title>
          <description>Duration of hospitalization in days for enrolled subjects</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="13.1"/>
                    <measurement group_id="O2" value="11.8" spread="6.5"/>
                    <measurement group_id="O3" value="9.1" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of PICU Stay in Days</title>
        <description>Duration of PICU stay in days for enrolled subjects</description>
        <time_frame>Pre-treatment through 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Placebo controlled (normal saline) daily for 3 days
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin (10 mg/kg)</title>
            <description>10 mg/kg IV Azithromycin daily for 3 days
Azithromycin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Azithromycin (20 mg/kg)</title>
            <description>20 mg/kg IV Azithromycin daily for 3 days
Azithromycin 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of PICU Stay in Days</title>
          <description>Duration of PICU stay in days for enrolled subjects</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="4.4"/>
                    <measurement group_id="O2" value="8.1" spread="5.8"/>
                    <measurement group_id="O3" value="5.4" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Lung Matrix Metalloproteinase (MMP) Level</title>
        <description>To determine the concentration of MMP-9 levels in the lung compartment</description>
        <time_frame>Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Placebo controlled (normal saline) daily for 3 days
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Azithromycin (10 mg/kg)</title>
            <description>10 mg/kg IV Azithromycin daily for 3 days
Azithromycin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Azithromycin (20 mg/kg)</title>
            <description>20 mg/kg IV Azithromycin daily for 3 days
Azithromycin 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Matrix Metalloproteinase (MMP) Level</title>
          <description>To determine the concentration of MMP-9 levels in the lung compartment</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13743" spread="23831"/>
                    <measurement group_id="O2" value="1448" spread="1478"/>
                    <measurement group_id="O3" value="1908" spread="2588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline through 3 weeks (for duration of PICU stay)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Placebo controlled (normal saline) daily for 3 days
Placebo</description>
        </group>
        <group group_id="E2">
          <title>Azithromycin (10 mg/kg)</title>
          <description>10 mg/kg IV Azithromycin daily for 3 days
Azithromycin 10 mg</description>
        </group>
        <group group_id="E3">
          <title>Azithromycin (20 mg/kg)</title>
          <description>20 mg/kg IV Azithromycin daily for 3 days
Azithromycin 20mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michele Kong, PI</name_or_title>
      <organization>UAB</organization>
      <phone>205-6389387</phone>
      <email>mkong@peds.uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

